Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
Want to see AU:IBX full AI Analyst Report?
Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.01
â–¼(-60.00% Downside)
Action:Reiterated
Date:06/26/26
The score is driven primarily by weak financial performance (zero revenue in 2025, persistent losses, negative equity, and ongoing cash burn), which outweighs only modestly mixed technical signals. Valuation is also constrained by continued losses (negative P/E) and the absence of dividend support.
Positive Factors
Proprietary MagSense platform
The proprietary MagSense magnetic‑nanoparticle imaging platform represents a durable technological advantage. Owning a differentiated detection modality and related IP can create barriers to entry, enabling future licensing, partnerships and clinical differentiation if validation and regulatory progress continue.
Negative Factors
Zero revenue in 2025
Revenue falling to zero in 2025 shows lack of commercial traction and heightens execution risk. Without product sales the company must rely on external capital to fund trials and commercialization, increasing financing, dilution and project‑timing risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary MagSense platform
The proprietary MagSense magnetic‑nanoparticle imaging platform represents a durable technological advantage. Owning a differentiated detection modality and related IP can create barriers to entry, enabling future licensing, partnerships and clinical differentiation if validation and regulatory progress continue.
Read all positive factors
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.89M
Dividend YieldN/A
Average Volume (3M)16.05M
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth-100.00%
EPS Growth68.62%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding490,590,240
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Imagion Biosystems Ltd. Business Overview & Revenue Model
Company Description
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic r...
How the Company Makes Money
null...
Imagion Biosystems Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.67M | 1.08M | 473.43K | 232.87K |
| Gross Profit | -8.81K | 2.26M | -279.83K | -3.14M | -2.47M |
| EBITDA | -3.58M | -700.09K | -10.30M | -11.03M | -5.62M |
| Net Income | -4.31M | -2.07M | -12.47M | -9.81M | -6.02M |
Balance Sheet | |||||
| Total Assets | 2.04M | 2.80M | 4.59M | 9.98M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.85M | 2.67M | 227.08K | 4.45M | 13.39M |
| Total Debt | 2.56M | 2.85M | 6.04M | 4.60M | 46.02K |
| Total Liabilities | 4.21M | 5.09M | 8.37M | 5.30M | 809.88K |
| Stockholders Equity | -2.16M | -2.28M | -3.79M | 4.68M | 13.31M |
Cash Flow | |||||
| Free Cash Flow | -4.04M | -1.27M | -8.51M | -9.21M | -5.29M |
| Operating Cash Flow | -4.04M | -1.27M | -8.32M | -8.70M | -5.07M |
| Investing Cash Flow | 0.00 | 83.74K | -190.38K | -468.73K | -310.09K |
| Financing Cash Flow | 3.24M | 3.61M | 4.29M | -962.06K | 5.15M |
Imagion Biosystems Ltd. Technical Analysis
Negative
0.03
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
31.59
Neutral
70.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IBX, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 31.59 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IBX.
Imagion Biosystems Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$56.13M | 25.73 | 72.82% | ― | 22.56% | 19.47% | |
54 Neutral | AU$76.72M | -8.86 | -37.14% | ― | 4.66% | 12.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$108.60M | -6.50 | -164.12% | ― | -14.85% | -41.04% | |
42 Neutral | AU$5.89M | -0.77 | 142.99% | ― | -100.00% | 68.62% | |
39 Underperform | AU$28.76M | -3.92 | -164.22% | ― | ― | 26.04% |
* Healthcare Sector Average
AU:IBX
Imagion Biosystems Ltd.
0.01
0.00
0.00%
AU:BDX
BCAL Diagnostics Limited
0.08
0.02
30.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.12
0.09
283.33%
AU:CTE
Cryosite Limited
1.15
0.41
55.41%
AU:IIQ
Inoviq Ltd
0.55
0.18
47.30%
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems Issues New Unquoted Performance Rights Under Employee Scheme
Jun 25, 2026
Imagion Biosystems has notified the market of the issue of new unquoted equity securities in the form of performance rights under its employee incentive scheme. The company will grant 2,200,000 Class D performance rights and 4,000,000 Class E perf...
Imagion Biosystems Updates Appendix 3B on Director Securities Issue
Jun 25, 2026
Imagion Biosystems Limited has lodged an updated Appendix 3B with the ASX detailing a proposed issue of securities via a placement or similar structure. The filing confirms that the company is seeking quotation of the new securities on the ASX onc...
Imagion Biosystems Plans New Share and Option Placement on ASX
Jun 24, 2026
Imagion Biosystems Limited has notified the Australian Securities Exchange of a proposed placement involving the issue of up to 6,250,000 ordinary fully paid shares and 3,125,000 options. The options are planned to expire in December 2027, with th...
Imagion Biosystems Plans Major Share and Option Issue to Bolster Capital Base
Jun 24, 2026
Imagion Biosystems has notified the ASX of a proposed capital raising through the issue of up to 263,153,949 fully paid ordinary shares and 156,250,000 options expiring in December 2027, with an expected issue date in August 2026. The placement, c...
Imagion Biosystems plans sizeable share issue to bolster capital base
Jun 24, 2026
Imagion Biosystems has lodged an Appendix 3B with the ASX detailing a proposed placement or other type of securities issue of up to 49,346,051 fully paid ordinary shares. The new shares are expected to be issued on 30 June 2026, expanding the comp...
Imagion Biosystems Raises $3.75m to Launch MagSense HER2 Clinical Trial
Jun 24, 2026
Imagion Biosystems has secured firm commitments for a $3.75 million equity placement to sophisticated investors and family offices, priced at $0.012 per share with free attaching listed options, following U.S. FDA clearance of its Investigational ...
Imagion Biosystems Requests Trading Halt Ahead of Capital Raising
Jun 22, 2026
Imagion Biosystems has requested a trading halt on its securities on the Australian Securities Exchange as it prepares a material announcement related to a capital raising. The halt, granted under ASX Listing Rule 17.1, will remain in place until ...
Imagion Biosystems wins FDA IND clearance for MagSense HER2 breast cancer trial
Jun 1, 2026
Imagion Biosystems has received U.S. FDA clearance of its Investigational New Drug application for the MagSense HER2 Imaging Agent, allowing a Phase 1b/2 clinical trial in HER2-positive breast cancer patients to proceed. The approval confirms that...
Imagion Biosystems Options Lapse, Simplifying Capital Structure
May 28, 2026
Imagion Biosystems has reported the expiry of a series of listed options with the ASX code IBXAAT, which were due to expire on 26 May 2026 with an exercise price of $1.496. A total of 699,897 options lapsed unexercised, resulting in a reduction of...
Imagion Biosystems AGM Backs Board, Incentive Plan and Capital Flexibility
May 26, 2026
Imagion Biosystems reported the results of its annual general meeting held on 26 May 2026, with all resolutions put to shareholders passed by the required majorities. The adoption of the remuneration report and the election of directors, including...
Imagion Biosystems outlines molecular MRI strategy and investor risk caveats
May 26, 2026
Imagion Biosystems has released an investor presentation outlining its focus on molecular MRI as a next generation imaging platform for early cancer detection. The deck is presented as informational only, with extensive legal and risk disclosures ...
Imagion Biosystems advances MagSense cancer imaging with first FDA IND filing
May 26, 2026
Imagion Biosystems used its 2025 Annual General Meeting to underline progress in developing its MagSense molecular imaging platform, which aims to offer safer, more targeted MRI contrast agents than conventional media and a competitive alternative...
Imagion Biosystems director adjusts holding of performance options
May 8, 2026
Imagion Biosystems has reported a change in the equity interests held by director Robert Romeo Proulx, as disclosed in an updated notice to the ASX. The filing details the disposal of 50,000 unlisted performance options at no consideration, adjust...
Imagion Biosystems Options Lapse, Trimming Potential Dilution
May 4, 2026
Imagion Biosystems Limited has reported the cessation of a tranche of listed options on the ASX, identified by the code IBXAAA, which expired unexercised on 1 May 2026. The expiry of 68,750 options with an exercise price of $1.12 slightly reduces ...
Imagion Biosystems moves 2026 AGM online and digitises shareholder communications
Apr 24, 2026
Imagion Biosystems Limited has convened its 2026 Annual General Meeting, to be held virtually via webinar on 26 May at 10:00am AEST, reflecting ongoing adoption of online formats for shareholder meetings. The company has shifted to electronic dist...
Imagion Biosystems Issues New Unquoted Convertible Notes and Options
Apr 23, 2026
Imagion Biosystems has notified the ASX of the issue of 330,000 unquoted convertible notes and more than 10.6 million unquoted options, both dated 23 April 2026. The options, which expire in April 2029 with an exercise price of $0.0297, and the co...
Imagion Biosystems Secures Additional Convertible Note Funding and Amends Terms
Apr 23, 2026
Imagion Biosystems has adjusted its funding structure under an existing Convertible Securities Agreement, which provides up to $15 million from U.S.-based investors Mercer Street Global Opportunity Fund and affiliated C/M Capital Partners. The com...
Imagion Biosystems advances MagSense breast cancer trial toward U.S. Phase 2 start
Apr 23, 2026
Imagion Biosystems has submitted its first Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 2 clinical trial of its MagSense imaging agent in HER2-positive breast cancer patients. The company has completed ...
Imagion Biosystems plans capital raise via convertible notes and options issue
Apr 16, 2026
Imagion Biosystems has notified the ASX of a proposed issue of new securities as part of a placement or similar capital-raising transaction, with an intended issue date of April 23, 2026. The company plans to issue up to 330,000 convertible notes ...
Imagion Biosystems Secures Extra Funding and Extends Note Maturities
Apr 8, 2026
Imagion Biosystems has secured an additional US$300,000 in short‑term funding from a fund managed by U.S.‑based C/M Capital Partners, under its existing convertible securities framework originally established with Mercer Street Global ...
Imagion Biosystems Sets 2026 AGM Date and Director Nomination Deadline
Apr 7, 2026
Imagion Biosystems has scheduled its 2026 Annual General Meeting for 26 May 2026 in Melbourne and has set 5pm AEST on 14 April 2026 as the deadline for shareholders to submit nominations for candidates to stand for election as directors. The forth...
Imagion Biosystems Reports Expiry of Unexercised Options
Apr 2, 2026
Imagion Biosystems Limited has notified the ASX of the cessation of a class of options, with 353,474 IBXAAR options expiring on March 23, 2026, without being exercised or converted. The expiry of these options slightly reduces the company’s ...
Imagion Biosystems addresses late ASX filing on convertible note repayment
Apr 2, 2026
Imagion Biosystems has advised that it recently lodged an Appendix 3H with the ASX relating to the part repayment of convertible notes held by Mercer Street Global Opportunity Fund, after the filing was submitted later than required due to an admi...
Imagion Biosystems Redeems 300,000 Convertible Notes Without Conversion
Apr 2, 2026
Imagion Biosystems has reported a change to its capital structure following the cessation of a tranche of its convertible securities. The company notified the ASX that 300,000 IBXAAQ convertible notes have been repaid or redeemed without conversio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.